Clinical Study Results
How many participants had adverse reactions?
There were 36.5% of participants who had adverse reactions during the study. This
was 132 out of 362 participants.
• 43.9% of participants who got anifrolumab had adverse reactions during the
study. This was 79 out of 180 participants.
• 29.1% of participants who got the placebo had adverse reactions during the
study. This was 53 out of 182 participants.
There were 2.2% of participants who stopped getting treatment due to adverse
reactions they had during the study. This was 8 out of 362 participants.
• 0.6% of participants stopped getting anifrolumab because of adverse reactions
they had during the study. This was 1 out of 180 participants.
• 3.8% of participants stopped getting the placebo because of adverse reactions
they had during the study. This was 7 out of 182 participants.
What adverse reactions did the participants have?
The most common adverse reaction was infection of the upper airways of the nose
and throat.
The table on the next page shows the most common adverse reactions that
happened in 4 or more participants while they were getting study treatment.
There were other adverse reactions, but these happened in fewer participants.
10